浅表性膀胱癌的免疫疗法。
Immunotherapy for superficial bladder cancer.
作者信息
Schenk-Braat Ellen A M, Bangma Chris H
机构信息
Department of Urology, Josephine Nefkens Institute, Room Be 362, PO Box 1738, 3000, DR Rotterdam, The Netherlands.
出版信息
Cancer Immunol Immunother. 2005 May;54(5):414-23. doi: 10.1007/s00262-004-0621-x. Epub 2004 Nov 23.
Abstract
The treatment of superficial bladder cancer requires adjuvant therapies besides transurethral resection because of a high recurrence rate after this standard treatment alone. Current adjuvant therapies involve intravesical chemotherapy for patients at low and intermediate risk for recurrence and progression, and intravesical bacillus Calmette-Guérin for patients at intermediate and high risk. However, these adjuvant therapies fail in a significant number of patients, dictating the need for new and improved adjuvant treatment modalities for superficial bladder cancer. Immunotherapy aiming at the modulation of the immune system of the patient is a promising alternative adjuvant. This review discusses the current status of the clinical development of various immunotherapy approaches for superficial bladder cancer, including passive immunotherapy, immune stimulants, immunogene therapy and cancer vaccination.
摘要
由于单纯经尿道切除术后浅表性膀胱癌的复发率较高，因此除经尿道切除外，还需要辅助治疗。目前的辅助治疗包括对复发和进展风险较低及中等的患者进行膀胱内化疗，以及对复发和进展风险中等及较高的患者进行膀胱内卡介苗治疗。然而，这些辅助治疗在相当多的患者中失败，这表明需要新的、改进的浅表性膀胱癌辅助治疗方式。旨在调节患者免疫系统的免疫疗法是一种有前景的替代辅助疗法。本文综述了浅表性膀胱癌各种免疫疗法的临床开发现状，包括被动免疫疗法、免疫刺激剂、免疫基因疗法和癌症疫苗接种。
相似文献
1
Immunotherapy for superficial bladder cancer.浅表性膀胱癌的免疫疗法。
Cancer Immunol Immunother. 2005 May;54(5):414-23. doi: 10.1007/s00262-004-0621-x. Epub 2004 Nov 23.
2
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.经尿道治疗非肌肉浸润性膀胱癌：系统评价和荟萃分析。
J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24.
3
Diagnosis and management of superficial bladder cancer.浅表性膀胱癌的诊断与管理
Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. doi: 10.1067/mcn.2001.117539.
4
[Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].[浅表性膀胱癌的膀胱内辅助化疗——萨克森州的一项调查结果]
Aktuelle Urol. 2005 Aug;36(4):337-41. doi: 10.1055/s-2004-830188.
5
Intravesical therapy of superficial bladder cancer.浅表性膀胱癌的膀胱内治疗
Curr Pharm Des. 2000 Feb;6(3):345-59. doi: 10.2174/1381612003401019.
6
Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.卡介苗无反应的非肌层浸润性膀胱癌的膀胱内及其他膀胱保留疗法
Urol Oncol. 2016 Jun;34(6):279-89. doi: 10.1016/j.urolonc.2015.12.004. Epub 2016 Jan 14.
7
Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.浅表性膀胱肿瘤的治疗：成就与需求。欧洲癌症研究与治疗组织泌尿生殖系统肿瘤协作组
Eur Urol. 2000;37 Suppl 3:1-9. doi: 10.1159/000052386.
8
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.浅表性膀胱癌辅助治疗的随机多中心试验：单纯经尿道切除术与经尿道切除术加丝裂霉素C以及经尿道切除术加卡介苗。参与研究的诊所。
J Urol. 1996 Sep;156(3):962-6. doi: 10.1016/s0022-5347(01)65673-8.
9
Intravesical Bacillus Calmette-Guérin treatment for superficial bladder cancer: results after 15 years of experience.
Anticancer Res. 1991 May-Jun;11(3):1253-8.
10
Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.单剂量即刻化疗联合辅助诱导卡介苗治疗高危非肌层浸润性膀胱癌患者可降低复发和进展风险。
Int J Urol. 2022 Aug;29(8):867-875. doi: 10.1111/iju.14926. Epub 2022 May 16.
引用本文的文献
1
Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.尿路上皮细胞癌的治疗策略和代谢途径调控：全面综述。
Int J Mol Sci. 2020 Nov 26;21(23):8993. doi: 10.3390/ijms21238993.
2
Combined lectin- and immuno-histochemistry (CLIH) for applications in cell biology and cancer diagnosis: Analysis of human urothelial carcinomas.用于细胞生物学和癌症诊断的凝集素和免疫组织化学联合检测（CLIH）：人尿路上皮癌分析。
Eur J Histochem. 2020 Jul 1;64(3):3141. doi: 10.4081/ejh.2020.3141.
3
Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer.外泌体携带 ErbB2/CRK 诱导前转移龛中的血管生长，并促进膀胱癌转移。
Cancer Sci. 2019 Jul;110(7):2119-2132. doi: 10.1111/cas.14080. Epub 2019 Jun 24.
4
Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.小鼠膀胱原位人膀胱癌（mio-hBC）模型的建立。
Am J Clin Exp Urol. 2018 Dec 20;6(6):245-259. eCollection 2018.
5
Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway.葛根素通过mTOR/p70S6K信号通路抑制膀胱癌细胞增殖。
Oncol Lett. 2018 Jan;15(1):167-174. doi: 10.3892/ol.2017.7298. Epub 2017 Oct 31.
6
Methotrexate-coupled nanoparticles and magnetic nanochemothermia for the relapse-free treatment of T24 bladder tumors.甲氨蝶呤偶联纳米颗粒与磁性纳米热疗用于T24膀胱肿瘤的无复发生物治疗
Int J Nanomedicine. 2017 Apr 6;12:2793-2811. doi: 10.2147/IJN.S120969. eCollection 2017.
7
How to obtain good morphology and antigen detection in the same tissue section?如何在同一张组织切片上获得良好的形态学表现和抗原检测结果？
Protoplasma. 2017 Sep;254(5):1931-1939. doi: 10.1007/s00709-017-1085-0. Epub 2017 Feb 10.
8
Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell aggressiveness.双链肿瘤抑制性微小RNA-145（miR-145-5p和miR-145-3p）对UHRF1的调控：抑制膀胱癌细胞的侵袭性。
Oncotarget. 2016 May 10;7(19):28460-87. doi: 10.18632/oncotarget.8668.
9
Local immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.局部免疫刺激可招募疫苗特异性CD8 T细胞并增强膀胱肿瘤的消退。
Oncoimmunology. 2015 May 22;4(7):e1016697. doi: 10.1080/2162402X.2015.1016697. eCollection 2015 Jul.
10
Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF- alpha/TNFR1 pathway in vitro and in vivo.华蟾素在体外和体内通过Fas/Fasl和TNF-α/TNFR1途径抑制人膀胱癌细胞生长。
J Exp Clin Cancer Res. 2015 Feb 25;34(1):21. doi: 10.1186/s13046-015-0134-9.
本文引用的文献
1
MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides.MAGE - A8在膀胱移行细胞癌中的过表达：两种肿瘤相关抗原肽的鉴定
Br J Cancer. 2004 Jul 19;91(2):398-407. doi: 10.1038/sj.bjc.6601968.
2
Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.使用重组卡介苗DNA疫苗和电穿孔基因免疫疗法治疗膀胱癌
Cancer Gene Ther. 2004 Mar;11(3):194-207. doi: 10.1038/sj.cgt.7700658.
3
Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma.用表达γ干扰素的重组卡介苗对实验性膀胱癌进行免疫治疗。
J Immunother. 2004 Mar-Apr;27(2):116-23. doi: 10.1097/00002371-200403000-00005.
4
Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.使用重组卡介苗DNA疫苗和白细胞介素-12 DNA疫苗治疗膀胱癌的免疫疗法。
J Urol. 2004 Mar;171(3):1343-7. doi: 10.1097/01.ju.0000103924.93206.93.
5
The cancer/testis genes: review, standardization, and commentary.癌症/睾丸基因：综述、标准化及评论
Cancer Immun. 2004 Jan 23;4:1.
6
The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.
Clin Cancer Res. 2003 Nov 15;9(15):5550-8.
7
Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.使用逆转录病毒载体通过CD40配体基因的体外表达诱导的针对膀胱癌的抗肿瘤免疫。
Cancer Gene Ther. 2003 Nov;10(11):833-9. doi: 10.1038/sj.cgt.7700627.
8
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.树突状细胞疫苗治疗播散性黑色素瘤患者的I/II期研究。
Cancer Immunol Immunother. 2004 Feb;53(2):125-34. doi: 10.1007/s00262-003-0429-0. Epub 2003 Nov 5.
9
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.一项随机II期试验的临床和免疫学结果，该试验采用四种黑色素瘤肽进行疫苗接种，这些肽要么与粒细胞-巨噬细胞集落刺激因子联合作为佐剂给药，要么负载于树突状细胞上。
J Clin Oncol. 2003 Nov 1;21(21):4016-26. doi: 10.1200/JCO.2003.10.005.
10
Nonviral cytokine gene therapy on an orthotopic bladder cancer model.非病毒细胞因子基因疗法在原位膀胱癌模型上的应用
Clin Cancer Res. 2003 Oct 1;9(12):4522-8.
Zotero 插件